When the patient shows progressive, symptomatic or radiographic disease, or the lack of antimicrobial conversion confirms treatment refractoriness with oral therapy, how do you decide between systemic IV amikacin and the liposome inhaled suspension?

When the patient shows progressive, symptomatic or radiographic disease, or the lack of antimicrobial conversion confirms treatment refractoriness with oral therapy, how do you decide between systemic IV amikacin and the liposome inhaled suspension?

CLICK HERE FOR CME CREDIT

When the patient shows progressive, symptomatic or radiographic disease, or the lack of antimicrobial conversion confirms treatment refractoriness with oral therapy, how do you decide between systemic IV amikacin and the liposome inhaled suspension?

Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | NTM-Pulmonary Infection Intelligence Zone

Presenter

Patrick Flume, MD

Patrick Flume, MD

Professor of Medicine and Pediatrics
Medical University of South Carolina
Powers-Huggins Endowed Chair for Cystic Fibrosis
University of South Carolina
Charleston, South Carolina